Choose your country to see the products for your location
A study published in Modern Pathology by researchers from Semmelweis University (Budapest, Hungary), in collaboration with scientists from MRC Holland, utilised MLPA and digitalMLPA in combination with DNA and RNA sequencing to extensively characterise a nationwide cohort of 192 pediatric acute lymphoblastic leukemia (ALL) patients.
Action may be required from users of Coffalyser.Net, our free analysis software. Users of the latest version of Coffalyser.Net (v.250317.1029) do not need to perform any action. Users of v.240129.1959 are required to renew their license which is easy to do and free of charge. Users of older versions of Coffalyser.Net are required to update to version v.240129.1959 or v.250317.1029. This is required for users making use of both preconfigured, as well as custom SQL Servers.
We have successfully obtained our certification under the new In Vitro Diagnostic Regulation (IVDR; 2017/746)! The first batch of flagship products are already available on the market under the new IVDR, well in advance of the transition period deadline.
A study published in Modern Pathology by researchers from Semmelweis University (Budapest, Hungary), in collaboration with scientists from MRC Holland, utilised MLPA and digitalMLPA in combination with DNA and RNA sequencing to extensively characterise a nationwide cohort of 192 pediatric acute lymphoblastic leukemia (ALL) patients.
Action may be required from users of Coffalyser.Net, our free analysis software. Users of the latest version of Coffalyser.Net (v.250317.1029) do not need to perform any action. Users of v.240129.1959 are required to renew their license which is easy to do and free of charge. Users of older versions of Coffalyser.Net are required to update to version v.240129.1959 or v.250317.1029. This is required for users making use of both preconfigured, as well as custom SQL Servers.
We have successfully obtained our certification under the new In Vitro Diagnostic Regulation (IVDR; 2017/746)! The first batch of flagship products are already available on the market under the new IVDR, well in advance of the transition period deadline.
Join our mailing list to receive the latest information about our products, technologies and website.